Convalescent plasma to treat COVID-19

Evan M. Bloch

doi:10.1182/BLOOD.2020007714

Convalescent plasma to treat COVID-19

Evan M. Bloch

School of Medicine

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, non-transfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.

Original language	English (US)
Pages (from-to)	654-655
Number of pages	2
Journal	Blood
Volume	136
Issue number	6
DOIs	https://doi.org/10.1182/BLOOD.2020007714
State	Published - Aug 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/BLOOD.2020007714

Cite this

@article{da50633d4b1541fcb5aa36b05a2885c2,

title = "Convalescent plasma to treat COVID-19",

abstract = "In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, non-transfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.",

author = "Bloch, {Evan M.}",

note = "Publisher Copyright: {\textcopyright} 2020 by The American Society of Hematology.",

year = "2020",

month = aug,

doi = "10.1182/BLOOD.2020007714",

language = "English (US)",

volume = "136",

pages = "654--655",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "6",

}

TY - JOUR

T1 - Convalescent plasma to treat COVID-19

AU - Bloch, Evan M.

PY - 2020/8

Y1 - 2020/8

N2 - In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, non-transfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.

AB - In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, non-transfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.

UR - http://www.scopus.com/inward/record.url?scp=85089170178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089170178&partnerID=8YFLogxK

U2 - 10.1182/BLOOD.2020007714

DO - 10.1182/BLOOD.2020007714

M3 - Review article

C2 - 32761219

AN - SCOPUS:85089170178

SN - 0006-4971

VL - 136

SP - 654

EP - 655

JO - Blood

JF - Blood

IS - 6

ER -

Convalescent plasma to treat COVID-19

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this